SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-23-054264
Filing Date
2023-11-02
Accepted
2023-11-02 21:24:04
Documents
2
Period of Report
2023-11-02

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 1607
2 POA DOCUMENT poa.txt EX-24 3573
  Complete submission text file 0001209191-23-054264.txt   6601
Mailing Address 430 E. 29TH STREET FLOOR 14 NEW YORK NY 10016
Business Address 430 E. 29TH STREET FLOOR 14 NEW YORK NY 10016 (212) 547-9879
Lexeo Therapeutics, Inc. (Issuer) CIK: 0001907108 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O LEXEO THERAPEUTICS, INC. 345 PARK AVENUE SOUTH, 6TH FLOOR NEW YORK NY 10010
Business Address
Davitian Bernard (Reporting) CIK: 0001994973 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-41855 | Film No.: 231374297